Montelucaste Tolife (Montelukast Sodium)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1 on airway smooth‑muscle cells and inflammatory cells. By preventing leukotrienes from binding, it reduces bronchoconstriction, mucus secretion, and inflammatory cell recruitment, thereby improving airway patency and decreasing symptoms associated with asthma and allergic rhinitis.

The dosage of Montelucaste Tolife is determined by the prescribing clinician based on the patient’s age, weight, and specific condition. Typical regimens range from a once‑daily tablet for adults and children over 12 years, to weight‑based dosing for younger children, but the exact amount must be set by a qualified healthcare provider.

Safety data for montelukast during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus, and breastfeeding mothers should consult their physician, as the drug does appear in breast milk in small amounts. Professional guidance is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature control) and necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑sensitive asthma or those who prefer a once‑daily tablet, but it does not provide immediate bronchodilation like rescue inhalers and may be less effective for severe uncontrolled asthma when used alone.

Montelucaste Tolife tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or near heat sources, and discard any tablets that appear discolored or damaged.

The tablet is taken orally, usually once daily in the evening, with or without food, as directed by the prescriber. Swallow the tablet whole; do not crush, split, or chew unless specifically advised. Consistent timing helps maintain steady drug levels and optimizes control of asthma or allergic symptoms.

Although uncommon, serious adverse reactions can include allergic responses such as rash, angioedema, or anaphylaxis, and neuropsychiatric events like mood changes, depression, or suicidal thoughts. Patients should seek immediate medical attention if they experience severe skin reactions, breathing difficulties, or significant changes in mood or behavior.

Individuals with known hypersensitivity to montelukast sodium or any component of the tablet should avoid its use. It is also contraindicated in patients who have experienced severe allergic reactions to leukotriene‑modifying agents. Clinicians should evaluate each patient’s medical history before prescribing.